Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Umana

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|December 16, 2010
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsMichaela Patz, Polina Isaeva, Nche Forcob, et al.
Molecular Cancer Therapeutics|January 12, 2011
Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101Stephane Dalle, Lina Reslan, Timothee Besseyre de Horts, et al.
Cancer Research|September 6, 2005
Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineeringManfred Schuster, Pablo Umana, Claudia Ferrara, et al.
Plos One|January 6, 2021
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine modelFloriana Cremasco, Elena Menietti, Dario Speziale, et al.
Haematologica|October 29, 2017
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activitySylvia Herter, Frank Herting, Gunter Muth, et al.
Mabs|November 2, 2020
CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulinsChristian Jost, Diana Darowski, John Challier, et al.
Cancer Immunology, Immunotherapy : CII|November 19, 2016
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agentsSylvia Herter, Laura Morra, Ramona Schlenker, et al.
Protein Engineering, Design & Selection : PEDS|September 15, 2012
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processingSilke Metz, Christian Panke, Alexander K Haas, et al.
Pharmaceutics|December 28, 2021
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial FluidMiro Julian Eigenmann, Tine Veronica Karlsen, Marek Wagner, et al.
Journal for Immunotherapy of Cancer|July 28, 2022
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumorsSophia Stock, Mohamed-Reda Benmebarek, Anna-Kristina Kluever, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|December 16, 2010
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsMichaela Patz, Polina Isaeva, Nche Forcob, et al.
Molecular Cancer Therapeutics|January 12, 2011
Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101Stephane Dalle, Lina Reslan, Timothee Besseyre de Horts, et al.
Cancer Research|September 6, 2005
Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineeringManfred Schuster, Pablo Umana, Claudia Ferrara, et al.
Plos One|January 6, 2021
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine modelFloriana Cremasco, Elena Menietti, Dario Speziale, et al.
Haematologica|October 29, 2017
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activitySylvia Herter, Frank Herting, Gunter Muth, et al.
Mabs|November 2, 2020
CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulinsChristian Jost, Diana Darowski, John Challier, et al.
Cancer Immunology, Immunotherapy : CII|November 19, 2016
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agentsSylvia Herter, Laura Morra, Ramona Schlenker, et al.
Protein Engineering, Design & Selection : PEDS|September 15, 2012
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processingSilke Metz, Christian Panke, Alexander K Haas, et al.
Pharmaceutics|December 28, 2021
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial FluidMiro Julian Eigenmann, Tine Veronica Karlsen, Marek Wagner, et al.
Journal for Immunotherapy of Cancer|July 28, 2022
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumorsSophia Stock, Mohamed-Reda Benmebarek, Anna-Kristina Kluever, et al.
Pageof 5